시장보고서
상품코드
1150066

세계의 건선성 관절염 시장 : 점유율, 규모, 동향, 업계 분석 - 투여 경로별, 약제 클래스별, 유통 채널별, 지역별, 부문 예측(2022-2030년)

Psoriatic Arthritis Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral, Parenteral, Topical); By Drugs Class; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 114 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 건선성 관절염 시장 규모는 2030년까지 222억 달러에 달할 것으로 예측됩니다.

세계의 건선성 관절염(Psoriatic Arthritis) 시장에 대해 조사했으며, 시장 역학, 부문별 분석, 지역 분석, 기업 개요 등의 정보를 제공하고 있습니다.

목차

제1장 서론

  • 보고서 설명
    • 조사 목적
    • 시장 범위
    • 가정
  • 이해관계자

제2장 주요 요약

  • 시장 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보 출처
    • 1차 정보
    • 2차 정보

제4장 세계의 건선성 관절염 시장 인사이트

  • 건선성 관절염 - 업계 현황
  • 건선성 관절염 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porter's Five Forces 분석
    • 공급 기업의 협상력
    • 신규 참여업체의 위협
    • 구매자의 협상력
    • 대체품의 위협
    • 기존 기업간 경쟁력
  • PESTEL 분석
  • 건선성 관절염 시장 업계 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 건선성 관절염 시장 : 약제 클래스별

  • 주요 조사 결과
  • 서론
    • 세계의 건선성 관절염 시장 : 약제 클래스별(2018-2030년)
  • 비스테로이드성 항염증제(NSAIDs)
    • 세계의 건선성 관절염 시장 : 비스테로이드성 항염증제(NSAIDs)별, 지역별(2018-2030년)
  • 비생물학적 질환 변성성 항류마티스제(DMARD)
    • 세계의 건선성 관절염 시장 : 비생물학적 질환 변성성 항류마티스제(DMARD)별, 지역별(2018-2030년)
  • 생물학적 질환 변성성 항류마티스제(DMARD)
    • 세계의 건선성 관절염 시장 : 생물학적 질환 변성성 항류마티스제(DMARD)별, 지역별(2018-2030년)
  • 기타
    • 세계의 기타 건선성 관절염 시장 : 지역별(2018-2030년)

제6장 세계의 건선성 관절염 시장 : 투여 경로별

  • 주요 조사 결과
  • 서론
    • 세계의 건선성 관절염 시장 : 투여 경로별(2018-2030년)
  • 경구
    • 세계의 건선성 관절염 시장 : 경구별, 지역별(2018-2030년)
  • 비경구
    • 세계의 건선성 관절염 시장 : 비경구별, 지역별(2018-2030년)
  • 국소
    • 세계의 건선성 관절염 시장 : 국소별, 지역별(2018-2030년)

제7장 세계의 건선성 관절염 시장 : 유통 채널별

  • 주요 조사 결과
  • 서론
    • 세계의 건선성 관절염 시장 : 유통 채널별(2018-2030년)
  • 병원 약국
    • 세계의 건선성 관절염 시장 : 병원 약국별, 지역별(2018-2030년)
  • 소매 약국
    • 세계의 건선성 관절염 시장 : 소매 약국별, 지역별(2018-2030년)
  • 온라인 약국
    • 세계의 건선성 관절염 시장 : 온라인 약국별, 지역별(2018-2030년)

제8장 세계의 건선성 관절염 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 건선성 관절염 시장 평가 : 지역별(2018-2030년)
  • 북미
    • 약제 클래스별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 미국
    • 캐나다
  • 유럽
    • 약제 클래스별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
  • 아시아태평양
    • 약제 클래스별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
  • 중동 및 아프리카
    • 약제 클래스별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
  • 라틴아메리카
    • 약제 클래스별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 멕시코
    • 브라질
    • 아르헨티나

제9장 경쟁 상황

  • 사업 확대와 인수 분석
    • 사업 확대
    • 인수
  • 파트너십/협업/협정/전시회

제10장 기업 개요

  • AbbVie Inc
  • AstraZeneca PLC
  • Amgen Inc
  • Bausch Health Companies Inc
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc
  • Novartis International AG
  • Pfizer, Inc.
  • UCB S.A
KSM 22.11.25

The global psoriatic arthritis market size is expected to reach USD 22.20 billion by 2030, according to a new study by Polaris Market Research. The report "Psoriatic Arthritis Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral, Parenteral, Topical); By Drugs Class; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Some of the main drivers of the market growth include hectic lifestyles that exceed the maximum immune system, a rapidly aging population, growth in psoriasis incidence, increasing incomes that make enormous biologic treatment options more inexpensive, and a rise in the incidence of product portfolio approvals.

For instance, In March 2019, AbbVie Inc. announced that the interleukin-23 (IL-23) receptor SKYRIZI (risankizumab) has already been authorized by the Japanese Department of Health, Labour, and Welfare (MHLW) for adult patients being treated with psoriatic arthritis, generalized suppurative psoriasis, erythema psoriasis, and rheumatic diseases who haven't responded well.

The need for PsA medications for treatment is expected to rise due to the rising prevalence of psoriatic arthritis, an autoimmune illness brought on by the body's immune system attacking the skin and joints. People who already have plaque psoriasis are more likely to develop the condition. About 30% of people with psoriasis go on to develop PsA, an inflammatory disorder that affects the joints, according to a study released by Celgene Corporation.

The expansion of the market is anticipated to be fueled by the rising number of medication approvals from regulatory agencies. For instance, In December 2019, Pfizer Inc. declared that the USFDA had authorized its Infliximab product type, a monoclonal antibody (mAb) against tumor necrosis factor, as a product to Remicade for the treatment of individuals with rheumatoid arthritis, ulcerative colitis, Crohn's disease, ankylosing psoriatic arthritis, psoriatic arthritis, and plaque.

Psoriatic Arthritis Market Report Highlights

The online pharmacies segment is anticipated to grow at a significant CAGR over the forecast period due to increased internet use around the world, the comfort of online shopping, and the numerous discounts that are available through pharmacy sites.

The non-steroidal anti-inflammatory medicine segment is anticipated to dominate the market for treating PsA soon by earning the maximum share owing to the demand for immunosuppressive medications, robust sales of currently available goods, and growth in the number of launches of attractive pipeline candidates.

Asia Pacific is anticipated to grow with the fastest CAGR over the forecast period. One of the critical aspects expected to stimulate the development of biological therapies for psoriasis in China is the increasing incidence of obesity. Smoking, excessive alcohol consumption, and the development of unhealthy lifestyles are expected to drive the market in this country.

The global players include AbbVie, Amgen, AstraZeneca, Bausch Health, and Bristol-Myers Squibb.

Polaris Market Research has segmented the psoriatic arthritis market report based on drug class, route of administration, distribution channel, and region:

Psoriatic Arthritis, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)

Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)

Others

Psoriatic Arthritis, Route Of Administration Outlook (Revenue - USD Billion, 2018 - 2030)

Oral

Parenteral

Topical

Psoriatic Arthritis, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Psoriatic Arthritis, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Psoriatic Arthritis Market Insights

  • 4.1. Psoriatic Arthritis - Industry Snapshot
  • 4.2. Psoriatic Arthritis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in prevalence of psoriatic arthritis to fuel market growth
      • 4.2.1.2. Presence of a strong pipeline of drug to spur market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent regulations
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Psoriatic Arthritis Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Psoriatic Arthritis Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 5.3.1. Global Psoriatic Arthritis Market, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), by Region, 2018 - 2030 (USD Billion)
  • 5.4. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
    • 5.4.1. Global Psoriatic Arthritis Market, by Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), by Region, 2018 - 2030 (USD Billion)
  • 5.5. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
    • 5.5.1. Global Psoriatic Arthritis Market, by Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), by Region, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Other Psoriatic Arthritis Market, by Region, 2018 - 2030 (USD Billion)

6. Global Psoriatic Arthritis Market, by Route Of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 6.3. Oral
    • 6.3.1. Global Psoriatic Arthritis Market, by Oral, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Parenteral
    • 6.4.1. Global Psoriatic Arthritis Market, by Parenteral, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Topical
    • 6.5.1. Global Psoriatic Arthritis Market, by Topical, by Region, 2018 - 2030 (USD Billion)

7. Global Psoriatic Arthritis Market, by Distribuation Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Psoriatic Arthritis Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Psoriatic Arthritis Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Psoriatic Arthritis Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)

8. Global Psoriatic Arthritis Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Psoriatic Arthritis Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Psoriatic Arthritis Market - North America
    • 8.3.1. North America: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.3.4. Psoriatic Arthritis Market - U.S.
      • 8.3.4.1. U.S.: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.3.5. Psoriatic Arthritis Market - Canada
      • 8.3.5.1. Canada: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.4. Psoriatic Arthritis Market - Europe
    • 8.4.1. Europe: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.4. Psoriatic Arthritis Market - UK
      • 8.4.4.1. UK: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.5. Psoriatic Arthritis Market - France
      • 8.4.5.1. France: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.6. Psoriatic Arthritis Market - Germany
      • 8.4.6.1. Germany: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.7. Psoriatic Arthritis Market - Italy
      • 8.4.7.1. Italy: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.8. Psoriatic Arthritis Market - Spain
      • 8.4.8.1. Spain: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.9. Psoriatic Arthritis Market - Netherlands
      • 8.4.9.1. Netherlands: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.4.10. Psoriatic Arthritis Market - Russia
      • 8.4.10.1. Russia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.5. Psoriatic Arthritis Market - Asia Pacific
    • 8.5.1. Asia Pacific: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.4. Psoriatic Arthritis Market - China
      • 8.5.4.1. China: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.5. Psoriatic Arthritis Market - India
      • 8.5.5.1. India: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.6. Psoriatic Arthritis Market - Malaysia
      • 8.5.6.1. Malaysia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.7. Psoriatic Arthritis Market - Japan
      • 8.5.7.1. Japan: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.8. Psoriatic Arthritis Market - Indonesia
      • 8.5.8.1. Indonesia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.5.9. Psoriatic Arthritis Market - South Korea
      • 8.5.9.1. South Korea: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.6. Psoriatic Arthritis Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.4. Psoriatic Arthritis Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.5. Psoriatic Arthritis Market - UAE
      • 8.6.5.1. UAE: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.6. Psoriatic Arthritis Market - Israel
      • 8.6.6.1. Israel: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.6.7. Psoriatic Arthritis Market - South Africa
      • 8.6.7.1. South Africa: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
  • 8.7. Psoriatic Arthritis Market - Latin America
    • 8.7.1. Latin America: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.7.4. Psoriatic Arthritis Market - Mexico
      • 8.7.4.1. Mexico: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.7.5. Psoriatic Arthritis Market - Brazil
      • 8.7.5.1. Brazil: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)
    • 8.7.6. Psoriatic Arthritis Market - Argentina
      • 8.7.6.1. Argentina: Psoriatic Arthritis Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Psoriatic Arthritis Market, by Distribuation Channel, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Psoriatic Arthritis Market, by Route Of Administration, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca PLC
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Amgen Inc
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bausch Health Companies Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bristol-Myers Squibb Company
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Celgene Corp
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Eli Lilly and Company
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Johnson & Johnson Services, Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Novartis International AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Pfizer, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. UCB S.A
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제